Central Alerting System
View Alert


Originator: National Patient Safety Alert - DHSC

Issue date: 26-Jul-2024 09:13:08

This alert has been issued to:
  • Care Trusts
  • Mental Health Trusts
  • Specialists Trusts
  • Learning Disabilities Trusts
  • Mental Health & Social Care Trusts
  • Ambulance Trusts
  • Mental Health & Learning Disabilities Trusts
  • Acute Trusts
  • Community Trusts

  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • Social Care Providers (registered with CAS)
  • Special Health Authorities
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • Integrated Care Boards
  • DHSC Supply Disruption - Medicines
  • Community Pharmacy
  • Primary Care Networks
  • GP Practices 1

Action category: Action

Title: Shortage of Kay-Cee-L (potassium chloride 375mg/5ml) (potassium chloride 5mmol/5ml) syrup

Broadcast content:

***Please note this alert has been superseded by NatPSA/2024/011/DHSC, issued 21/10/2024***

Kay-Cee-L® (potassium chloride 5mmol/5ml) syrup will be out of stock from late September 2024. The resupply date is to be confirmed.

The supply disruption is caused by an amendment to the manufacturing process, requiring re-formulation, and revalidation of the product.

Sando-K® (potassium bicarbonate 400mg and potassium chloride 600mg) effervescent tablets remain available and can support a full increase in demand. One effervescent tablet contains 12mmol potassium.

Unlicensed potassium chloride oral solutions manufactured within the UK are available via Specials manufacturers.

Remaining supplies of Kay-Cee-L® syrup should be prioritised for patients requiring doses of less than 12mmol of potassium and where other preparations are not suitable (see Notes).

Care is needed to ensure selection of the most appropriate oral potassium supplement and delivery of the correct dosage.

This National Patient Safety Alert provides further background, clinical information and actions for providers.



Additional information: NHS England regions: please cascade this alert to community phamacy.

Alert reference: NatPSA/2024/008/DHSC

Action underway deadline: 30-Jul-2024

Action complete deadline: 12-Aug-2024

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency